NCT03721718 - Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

May 30, 2019

Study Completion Date

April 22, 2020

Conditions

Healthy

Interventions

BIOLOGICAL

GLS-5300

\[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)

DEVICE

Cellectra 2000 Electroporation

GLS-5300 administered ID followed by Cellectra 2000 Electroporation

Trial Locations (2)

Unknown

Seoul National University Bundang Hospital, Seongnam

Seoul National University Hospital, Seoul